Sun Pharmaceutical Industries Ltd. announced a set of changes early Jan. 22 as it rushed to contain a spiraling corporate governance crisis that has erased more than $3 billion of market value in under two months.
Distribution of its local drug business will move to one of its wholly-owned subsidiaries from Aditya Medisales, a firm controlled by Sun’s billionaire founder-owner Dilip Shanghvi, India’s largest drugmaker said in a filing. The company will also unwind $345 million of loans that have drawn investor scrutiny and appoint a new auditor at some of its units.
Dilip Shanghvi
Photographer: Kuni Takahashi/Bloomberg
The company also denied extending any ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.